Drug Combination Details
| General Information of the Combination (ID: C49580) | |||||
|---|---|---|---|---|---|
| Name | Luteolin NP Info | + | Oxaliplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Colorectal cancer
[ICD-11: 2B91]
|
Investigative | [1] | ||
|
Stomach cancer
[ICD-11: 2B72]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Induction | Cell cycle arrest in G0/G1 phase | ||||
| Up-regulation | Cytochrome c release | |||||
| In-vitro Model | SGC-7901 | CVCL_0520 | Human gastric cancer | Homo sapiens | ||
| Experimental
Result(s) |
Luteolin Suppresses the Proliferation of Gastric Cancer Cells and Acts in Synergy with Oxaliplatin through the Cyt c/caspase pathway. | |||||
| Experiment 2 Reporting the Effect of This Combination | [1] | |||||
| Biological
Regulation |
Induction | Cell cycle arrest in G0/G1 phase | ||||
| In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Luteolin can induce p53-mediated apoptosis regardless of oxaliplatin treatment and may eliminate oxaliplatin-resistant p53-null colorectal cells. | |||||
| β. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | GABPA | Molecule Info | ||
| Down-regulation | Expression | GSTA1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | GSTA2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | HMOX1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | NQO1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
| SW620 | CVCL_0547 | Colon adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway. | |||||
